Euroz Hartleys Upgrades BOT to Buy
Euroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.
